A multi-trial analysis published in BMJ Open found that GLP-1 receptor agonists (semaglutide and tirzepatide) reduce alcohol-related hospitalizations by 26% in adults with alcohol use disorder compared to other treatments. This is a genuine finding from peer-reviewed research analyzing electronic health records from over 40,000 patients, suggesting these weight-loss drugs may have an unexpected secondary benefit for alcohol use disorder. The study examined outcomes across four different trial populations including people with both AUD and type 2 diabetes, or AUD and obesity, strengthening the evidence base.